Publications by authors named "I Alacacioglu"
This retrospective one-center study demonstrates the complications related to high-dose therapy with autologous stem cell support (HDT) and the survival of multiple myeloma (MM) patients according to age groups. : We categorized the patients into two groups: those who were ≤65 years old (group 1) ( = 115) and those who were >65 years old (group 2) ( = 26). The mean duration of follow-up was 48 (1-125) months.
View Article and Find Full Text PDFTo determine the unmet needs and challenges in management, diagnosis, treatment, follow-up and patient-physician communication in acute leukemia (AL). The study was based on a modified Delphi approach. A questionnaire including the major potential obstacles was circulated twice among 13 hematologists.
View Article and Find Full Text PDFArticle Synopsis
- Glofitamab is a bi-specific antibody used to treat relapsed or refractory B-cell lymphoma, showing potential in a phase II trial, but real-world data is limited.
- A retrospective study in Turkey analyzed 43 DLBCL patients receiving glofitamab, revealing median overall survival of 8.8 months and a 1-year progression-free survival rate of 83%.
- While the treatment had promising effectiveness, toxicity was a significant concern, with deaths linked to disease progression and treatment-related side effects like cytokine release syndrome.
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) subtype characterized by overexpression of CCND1 and SOX11 genes. It is generally associated with clinically poor outcomes despite recent improvements in therapeutic approaches. The genes associated with the development and prognosis of MCL are still largely unknown.
View Article and Find Full Text PDFIntroduction: In multiple myeloma cases, a variety of prognostic parameters have been identified, which contain the Durie-Salmon classification and the international staging system (ISS) that takes the serum ß2 microglobulin and albumin levels, platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-lymphocyte ratio (MLR). This study investigates the effect of haemoglobin, albumin, lymphocyte and platelet (HALP) score which is a marker of inflammation status and nutrition, at the time of diagnosis for the patients with multiple myeloma on prognosis.
Methods: A total of 200 multiple myeloma patients with HALP scores calculated from serum haemoglobin, albumin, lymphocyte count and platelet levels at the time of diagnosis were retrospectively examined.